Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger A Moorehead

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Genes|July 31, 2019
Rodent Models Assessing Mammary Tumor Prevention by Soy or Soy IsoflavonesRoger A Moorehead
International Journal of Cancer|October 6, 2024
Transgenic overexpression of the miR-200b/200a/429 cluster prevents mammary tumor initiation in Neu/Erbb2 transgenic miceKatrina L Watson, Roger A Moorehead
BMC Cancer|August 8, 2013
Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic miceKatrina L Watson, Roger A Moorehead
BMC Cancer|November 11, 2011
Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptorsCraig I Campbell, Roger A Moorehead
International Journal of Oncology|January 25, 2021
Polycomb repressor complex 2 function in breast cancer (Review)Courtney J Martin, Roger A Moorehead
Plos One|February 23, 2018
A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206Paige M Chorner, Roger A Moorehead
BMC Developmental Biology|August 29, 2021
The miR-200 family in normal mammary gland developmentMajesta J Roth, Roger A Moorehead
Genes, Chromosomes & Cancer|January 1, 2019
Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrenceRobert A Jones, Roger A Moorehead
Journal of Mammary Gland Biology and Neoplasia|November 13, 2008
The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesisRobert A Jones, Roger A Moorehead
Cancer Cell International|September 26, 2014
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitorsLeanne Stalker, James Pemberton, Roger A Moorehead
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Genes|July 31, 2019
Rodent Models Assessing Mammary Tumor Prevention by Soy or Soy IsoflavonesRoger A Moorehead
International Journal of Cancer|October 6, 2024
Transgenic overexpression of the miR-200b/200a/429 cluster prevents mammary tumor initiation in Neu/Erbb2 transgenic miceKatrina L Watson, Roger A Moorehead
BMC Cancer|August 8, 2013
Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic miceKatrina L Watson, Roger A Moorehead
BMC Cancer|November 11, 2011
Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptorsCraig I Campbell, Roger A Moorehead
International Journal of Oncology|January 25, 2021
Polycomb repressor complex 2 function in breast cancer (Review)Courtney J Martin, Roger A Moorehead
Plos One|February 23, 2018
A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206Paige M Chorner, Roger A Moorehead
BMC Developmental Biology|August 29, 2021
The miR-200 family in normal mammary gland developmentMajesta J Roth, Roger A Moorehead
Genes, Chromosomes & Cancer|January 1, 2019
Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrenceRobert A Jones, Roger A Moorehead
Journal of Mammary Gland Biology and Neoplasia|November 13, 2008
The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesisRobert A Jones, Roger A Moorehead
Cancer Cell International|September 26, 2014
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitorsLeanne Stalker, James Pemberton, Roger A Moorehead
Pageof 4